4-methyl-6-(4-nitro-phenylsulfanyl)-pyrimidin-2-ylamine | 873407-26-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-methyl-6-(4-nitro-phenylsulfanyl)-pyrimidin-2-ylamine
• 英文别名: 4-Methyl-6-(4-nitro-phenylmercapto)-pyrimidin-2-ylamin；4-Methyl-6-(4-nitrophenyl)sulfanylpyrimidin-2-amine
• CAS: 873407-26-2
• 化学式: C₁₁H₁₀N₄O₂S
• 分子量: 262.292
• InChiKey: BCLGYUNCUJMAQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  123
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-methyl-6-(4-nitro-phenylsulfanyl)-pyrimidin-2-ylamine 在 potassium permanganate 、 铁粉 、 氯化铵 、 溶剂黄146 作用下， 生成 acetic acid-[4-(2-amino-6-methyl-pyrimidine-4-sulfonyl)-anilide]
  参考文献：
  名称：

  Ohta; Sudo, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1951, vol. 71, p. 45,48

  摘要：

  DOI：

文献信息

• The Amino Acid Sequence of the PKR‐eIF2α Phosphorylation Homology Domain of Hepatitis C Virus Envelope 2 Protein and Response to Interferon‐α
  作者：Alexandra Cochrane、Alexander Orr、Megan L. Shaw、Peter R. Mills、Elizabeth A. B. McCruden

  DOI：10.1086/315886

  日期：2000.11

  A region of the hepatitis C virus (HCV) envelope 2 protein, the protein kinase, PKR and early initiation factor 2α phosphorylation homology domain (PePHD), may be important in interferon (IFN)—α resistance. The PePHD was amplified by polymerase chain reaction and sequenced, and the amino acid sequence derived from pretreatment serum of 14 genotype 3—infected patients with a range of responses to IFN-α therapy. Only 1 patient had a PePHD variant. IFN-resistant PePHD variants present at low titers in pretreatment serum should be selected by therapy; therefore, the PePHD amino acid sequence was also obtained from serum collected during or after treatment in 5 patients with breakthrough or relapse of HCV RNA positivity. No difference was found between the pre- and posttreatment PePHD sequences. Thus, it appears that pretreatment sequencing of the PePHD would not enable clinicians to predict the treatment response. There was no evidence that IFN therapy exerts selection pressure in this region.

  丙型肝炎病毒（HCV）包膜2蛋白、蛋白激酶、PKR和早期启动因子2α磷酸化同源域（PePHD）区域可能对干扰素（IFN）-α抗性有重要作用。研究人员通过聚合酶链反应扩增PePHD并对其进行测序，从14名基因3型感染患者对IFN-α治疗有不同反应的预处理血清中提取氨基酸序列。只有1名患者有PePHD变异。治疗时应选择预处理血清中低滴度的IFN抗性PePHD变异；因此，研究人员还从5名HCV RNA阳性突破或复发患者治疗期间或治疗后采集的血清中提取了PePHD氨基酸序列。治疗前后的PePHD序列没有发现差异。因此，PePHD的预处理测序似乎无法帮助临床医生预测治疗反应。没有证据表明IFN治疗对该区域产生选择压力。
• Ohta; Sudo, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1951, vol. 71, p. 45,48
  作者：Ohta、Sudo

  DOI：——

  日期：——